Watson Biotech (300142.SZ) subsidiary's novel coronavirus mRNA vaccine obtained drug registration certificate

According to the Zhitong Finance App, Watson Biotech (300142.SZ) announced that Yuxi Watson Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, received the “Novel Coronavirus mRNA Vaccine” and “Drug Registration Certificate” approved and issued by the State Drug Administration on September 10, 2026. Based on mRNA platform technology, the company can continuously update and iteratively market the novel coronavirus mRNA vaccine of the corresponding popular strain according to the COVID-19 epidemic strain recommended by the World Health Organization (WHO) or China's disease prevention and control department to prevent diseases caused by the novel coronavirus infection (COVID-19) for people aged 18 and above.

According to reports, this vaccine is a third-generation COVID-19 mRNA vaccine developed iteratively by the company based on the mRNA platform technology strategy. Currently, mRNA technology is being used globally in cutting-edge biomedical technological innovation research, development and application fields. Since 2020, the company has continued to increase R&D investment in mRNA technology and established a leading domestic mRNA technology and industrialization platform. On the one hand, it has provided a new technology route for the development of novel preventive vaccines; at the same time, it has also laid a solid foundation for promoting tumor vaccines, protein replacement drugs, and In Vivo CAR-T in the field of treatment. The respiratory syncytial virus mRNA vaccine and freeze-dried herpes zoster mRNA vaccine developed by the company based on the mRNA technology platform have obtained clinical approval, and other therapeutic mRNA drugs are in the preclinical research stage.